PTC Therapeutics, Inc. (PTCT) Revenue History
Annual and quarterly revenue from 2014 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
PTCT Revenue Growth
Revenue Breakdown (FY 2025)
PTCT's revenue distribution by segment and geography for fiscal year 2025
By Product/Segment
By Geography
PTCT Revenue Analysis (2014–2025)
As of May 8, 2026, PTC Therapeutics, Inc. (PTCT) generated trailing twelve-month (TTM) revenue of $827.1 million, reflecting significant decline in growth of -76.8% year-over-year. The most recent quarter (Q1 2026) recorded $272.6 million in revenue, up 65.5% sequentially.
Looking at the longer-term picture, PTCT's 5-year compound annual growth rate (CAGR) stands at +35.4%, indicating outstanding long-term growth trajectory. The company achieved its highest annual revenue of $1.73 billion in 2025, representing a new all-time high.
Revenue diversification analysis shows PTCT's business is primarily driven by Collaboration and License Revenue (55%), Product (32%), and Royalty (13%). With over half of revenue concentrated in Collaboration and License Revenue, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including SRPT (-2.2% YoY), BMRN (+9.9% YoY), and RARE (+13.3% YoY), PTCT has underperformed the peer group in terms of revenue growth. Compare PTCT vs SRPT →
PTCT Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| PTCTCurrent | $827M | -76.8% | +35.4% | 49.5% | |
 SRPT | $2.2B | -2.2% | +32.4% | -29.9% | |
 BMRN | $3.2B | +9.9% | +11.6% | 16.6% | |
 RARE | $673M | +13.3% | +19.9% | -79.5% | |
 ALNY | $3.7B | +82.6% | +49.8% | 13.5% | |
 ACAD | $1.1B | +9.9% | +19.4% | 9.8% |
PTCT Historical Revenue Data (2014–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $1.73B | +114.5% | $1.66B | 95.9% | $856.5M | 49.5% |
| 2024 | $806.8M | -14.0% | $749.4M | 92.9% | $-302,570,000 | -37.5% |
| 2023 | $937.8M | +34.2% | $872.3M | 93.0% | $-439,502,000 | -46.9% |
| 2022 | $698.8M | +29.7% | $654.1M | 93.6% | $-447,409,000 | -64.0% |
| 2021 | $538.6M | +41.4% | $506.3M | 94.0% | $-374,443,000 | -69.5% |
| 2020 | $380.8M | +24.0% | $361.8M | 95.0% | $-431,768,000 | -113.4% |
| 2019 | $307.0M | +16.0% | $294.8M | 96.0% | $-241,158,000 | -78.6% |
| 2018 | $264.7M | +36.2% | $252.1M | 95.2% | $-115,685,000 | -43.7% |
| 2017 | $194.4M | +135.0% | $189.8M | 97.6% | $-64,292,000 | -33.1% |
| 2016 | $82.7M | +124.9% | $-34,928,000 | -42.2% | $-132,058,000 | -159.7% |
See PTCT's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs PTCT Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare PTCT vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonPTCT — Frequently Asked Questions
Quick answers to the most common questions about buying PTCT stock.
Is PTCT's revenue growth accelerating or slowing?
PTCT revenue declined -76.8% year-over-year, contrasting with the 5-year CAGR of +35.4%. TTM revenue fell to $827M. This reverses the prior growth trend.
What is PTCT's long-term revenue growth rate?
PTC Therapeutics, Inc.'s 5-year revenue CAGR of +35.4% reflects the variable expansion pattern. Current YoY growth of -76.8% is below this long-term average.
How is PTCT's revenue distributed by segment?
PTCT reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2014-2025 are available for download. Segment mix reveals concentration and diversification trends.